Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0248 | 0.2784 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0248 | 0.2784 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0088 | 0 | 0.5 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0248 | 0.2784 | 0.2784 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0248 | 0.2784 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0248 | 0.2784 | 1 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0248 | 0.2784 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0248 | 0.2784 | 0.2784 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0248 | 0.2784 | 0.5 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0088 | 0 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0248 | 0.2784 | 0.5 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0097 | 0.0152 | 0.0545 |
Schistosoma mansoni | hypothetical protein | 0.0248 | 0.2784 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0248 | 0.2784 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.0662 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0248 | 0.2784 | 0.2784 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0248 | 0.2784 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0248 | 0.2784 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0248 | 0.2784 | 0.2784 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0248 | 0.2784 | 0.2784 |
Onchocerca volvulus | 0.0248 | 0.2784 | 1 | |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0088 | 0 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0248 | 0.2784 | 0.5 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0248 | 0.2784 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0088 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0248 | 0.2784 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.0152 | 0.0545 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0248 | 0.2784 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0088 | 0 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.0248 | 0.2784 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0088 | 0 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0088 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0248 | 0.2784 | 0.2784 |
Chlamydia trachomatis | SWIB complex protein | 0.0248 | 0.2784 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0248 | 0.2784 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0088 | 0 | 0.5 |
Onchocerca volvulus | 0.0097 | 0.0152 | 0.0545 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.774 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.658 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.39 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.325 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.252 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.144 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.